Illustrative image.
Tasigna
Nilotinib
$9600.00
150mg · 3 × 112 capsules · 6 months supply
BrandBranded medicine· By Novartis
$1600.00 per month
Strength
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$22400a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
150mg
200mg
FDA boxed warningQt prolongation and sudden deaths
Nilotinib capsules prolongs the QT interval. Prior to nilotinib capsules administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments.
Sudden deaths have been reported in patients receiving nilotinib capsules. Do not administer nilotinib capsules to patients with hypokalemia, hypomagnesemia, or long QT syndrome.
Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.
Avoid food 2 hours before and 1 hour after taking the dose.
Nilotinib c
About Tasigna
Overview
Tasigna contains nilotinib, a kinase inhibitor supplied as capsules. It treats newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase in adults and children aged 1 year and older. It also treats chronic- or accelerated-phase Ph+ CML in adults whose prior treatment included imatinib and did not work or was not tolerated, and chronic-phase Ph+ CML in children aged 1 year and older whose prior kinase inhibitor treatment did not work or was not tolerated. Nilotinib works by blocking BCR-ABL, a protein involved in the growth of these leukemia cells.
What it treats
- Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase in adults and children aged 1 year and older. - Chronic-phase or accelerated-phase Ph+ CML in adults whose disease is resistant to prior treatment that included imatinib, or who could not tolerate that treatment. - Chronic-phase Ph+ CML in children aged 1 year and older whose disease is resistant to prior tyrosine kinase inhibitor treatment, or who could not tolerate that treatment.
Safety information
Side effects
Common side effects include nausea, rash, itching, headache, tiredness, vomiting, diarrhea, constipation, cough, joint pain, inflammation of the nose and throat, fever, and night sweats. Hair loss, dry skin, muscle pain or spasms, and abdominal pain have also been reported. Serious side effects include: • Changes in the heart’s electrical rhythm (QT prolongation), which can cause fainting, seizures, or death. Sudden deaths have been reported. Seek immediate medical attention for fainting or seizures. • Heart problems and blocked arteries affecting the heart, brain, or limbs. Seek immediate medical attention for sudden symptoms of heart or circulation problems. • Low platelet, white blood cell, or red blood cell counts, which can be severe and require treatment changes. • Serious bleeding, including fatal bleeding. Report any signs of bleeding to a doctor promptly. • Inflammation of the pancreas, raised pancreatic enzyme levels, and liver damage. Contact a doctor if you develop abdominal symptoms. • Fluid retention, including fluid around the heart or lungs or in the lungs. Contact a doctor promptly for unexpected rapid weight gain, swelling, or shortness of breath. • Changes in blood mineral levels and tumor lysis syndrome. • Slowed growth in children. Regular blood tests and heart rhythm checks are needed because some serious effects may be detected through monitoring. Growth and development should also be monitored in children.
FDA boxed warning
Qt prolongation and sudden deaths
Nilotinib capsules prolongs the QT interval. Prior to nilotinib capsules administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments.
Sudden deaths have been reported in patients receiving nilotinib capsules. Do not administer nilotinib capsules to patients with hypokalemia, hypomagnesemia, or long QT syndrome.
Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.
Avoid food 2 hours before and 1 hour after taking the dose.
Nilotinib c
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Tasigna (nilotinib) if you have low potassium, low magnesium or long QT syndrome, a heart rhythm disorder. Low potassium and magnesium must be corrected before treatment. Nilotinib can prolong the QT interval and cause a dangerous heart rhythm that may lead to fainting, seizures or death. Tell your prescriber if you have heart or blood vessel disease, cardiovascular risk factors, a history of pancreatitis, liver problems, electrolyte abnormalities, or have had your stomach completely removed. The capsules contain lactose and are not recommended for people with rare hereditary galactose intolerance, severe lactase deficiency with severe lactose intolerance, or glucose-galactose malabsorption. Do not take nilotinib with food. Medicines that strongly inhibit CYP3A4 or prolong the QT interval should be avoided during treatment because they can increase the risk of dangerous heart rhythms. Your prescriber should review your other medicines for interactions. Treatment requires heart rhythm checks and blood tests. Important risks include low blood cell counts, liver injury, pancreatitis, blocked arteries, serious bleeding, fluid retention and tumor lysis syndrome. Report bleeding, unexpected rapid weight gain, swelling or shortness of breath. Seek immediate medical attention for sudden symptoms of a heart or blood vessel problem. Children need monitoring of growth and development. Nilotinib may harm an unborn baby. Use effective contraception if you can become pregnant. Do not breastfeed during treatment.
Interactions
Tasigna (nilotinib) should not be taken with strong CYP3A inhibitors, which can raise nilotinib levels and increase the risk of toxicity, or strong CYP3A inducers, which can lower nilotinib levels and reduce its effectiveness. If a strong CYP3A inhibitor cannot be avoided, your prescriber will need to adjust your treatment. Avoid proton pump inhibitors (PPIs), which can lower nilotinib levels and reduce its effectiveness. H2 blockers or short-acting antacids may be used instead, but must be taken separately from nilotinib. Ask your doctor about the required timing. Avoid medicines that prolong the QT interval, an electrical measurement of heart rhythm, including certain medicines used to treat irregular heartbeats.
Using Tasigna
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label NILOTINIB CAPSULE [TORRENT PHARMACEUTICALS LIMITED] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Idamycin PFS
Idarubicin Hydrochloride
By Pfizer
Syringes · from 1 per pack
Also for leukemia
Brand $165.00
Venclexta
Venetoclax
Tablets · from 7 per pack
Also for leukemia
Brand from $121.00
Vesanoid
Tretinoin
Capsules · from 100 per pack
Also for leukemia
Brand $762.00
Xospata
Gilteritinib (as Fumarate)
By Astellas Pharma
Tablets · from 84 per pack
Also for leukemia
Brand $34,060.00